Buspirone chlorhydrate in the treatment of cerebellar ataxia;Clorhidrato de buspirona en el tratamiento de la ataxia cerebelosa

Revista de Neurologia

Volumn 35, Issue 4, 2002, Pages 301-305

  Andrade Filho, A S ^a   Passos Almeida, J ^b   Andrade Souza, V M ^c   Sena Pereira, L R ^c  

^a Instituto do Cerebro   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

Author keywords

Buspirone chlorhydrate; Cerebellar ataxia; Cerebellar atrophy; Clinical profile; Epidemiology; Treatment

Indexed keywords

BUSPIRONE; CARBAMAZEPINE; SEROTONIN AGONIST;

ADDICTION; ADULT; AGE; ARTICLE; BRAIN ATROPHY; BRAIN FUNCTION; CEREBELLAR ATAXIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; EPILEPSY; EVALUATION; FAMILIAL DISEASE; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE; PATIENT SELECTION; SCORING SYSTEM; TREATMENT OUTCOME; CLINICAL TRIAL;

ADULT; BUSPIRONE; CEREBELLAR ATAXIA; HUMANS; SEROTONIN AGONISTS; TREATMENT OUTCOME;

EID: 0037119555     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3504.2001006     Document Type: Article

References (21)

1. 1A agonist 8-OH-DPAT and ipsapirone in vitro. Eur J Pharmacol 1990; 148: 235-65.
2. Bishop GA, Ho RH, King JG. Localization of serotonin immunoreactivity in the opossum cerebellum. J Comp Neurol 1985; 235: 301-21.
3. Plaitakis A, van Woert MH, Hwang EC, Berl S. Thiamine deficiency: Selective impairment of the cerebellar serotoninergic system. J Neurochem 1978; 3: 1087-9.
4. Plaitakis A, Nicklas JN, Berl S. Thiamine deficiency: Selective impairment of the cerebellar serotoninergic system. Neurology 1978; 28:691-8.
5. Plaitakis A, Hwang EC, Woert MH, Szilagyi PE, Berl S. Effect of thiamin deficiency on brain neurotransmitter systems. Ann N Y Acad Sci 1982; 378: 367-81.
6. Raiteri M, Maura G, Barzizza A. Activation of presynaptic 5-hydroxytryptamine 1-like receptors on glutamatergic terminals inhibits N-methyl-D-aspartate-induced cyclic GMP production in rat cerebellar slices. J Pharmacol. Exp Ther 1991; 257: 1184-8.
7. Raiteri M, Maura G, Bonanno G, Pittaluga A. Differential pharmacology and function os two 5-HT receptors modulating transmitter release in rat cerebellum. J Pharmacol Exp Ther 1986; 237: 644-8.
8. Raiteri M, Maura G, Lottero P, Gastaldo L. Serotoninergic control of glutamatergic systems in the cerebellum serotoninergic control of glutamate systems in rat cerebellum. In Trouillas P, Fuxe K, eds. Serotonin, the Cerebellum and Ataxia. New York: Raven Press; 1993. p. 155-66.
9. Trouillas P, Garde A, Robert JM. Regression du syndrome cerebelleux sous administration a long terme du L-5HTP ou de l'association 5-HTP-benserazide: Vint cinq observations quantifiées et traitées par ordinateur. Rev Neurol (Paris) 1980; 12: 891.
10. Trouillas P, Garde A, Robert JM, Adeleine P. Regression de l'ataxie cerebelleuse humaine sous administration à long terme de 5-hydroxytryptophane. C R Seances Acad Sci III 1981; 292: 119-22.
11. 1A sur l'ataxie cérébelleuse: Une étude pilote. Rev Neurol (Paris) 1995; 151: 708-13.
12. Lou JS, Goldfarb L, Mc Shane L, Gatev P, Hallett M. Use of Buspirone for treatment of cerebellar ataxia: An open label study. Arch Neurol 1995; 52: 462-8.
13. Hjorth S, Carlsson A. Buspirone: Effects on central monoaminergic transmission. Possible relevance to animal experimental and clinical findings. Eur J Pharmacol 1982; 83: 299-303.
14. 1A receptors. Biol Psychiatry 1985; 20: 971-9.
15. Riblet LA, Eison AS, Eison MS, Taylor DP, Temple DL, VanderMaelen CP. Neuropharmacology of buspirone. Psychopathology 1984; 17 (Suppl 3): S69-78.
16. Eison AS, Eison MS, Stanley M, Riblet LA. Serotoninergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacol Biochem Behav 1986; 24: 701-7.
17. Trouillas P. The serotoninergic Hypothesis of cerebellar ataxia and its pharmacological consequences. In Trouillas P, Fuxe K, eds. Serotonin, the Cerebellum and Ataxia. New York: Raven Press; 1993. p. 323-34.
18. Trouillas P. The serotoninergic cerebellar system and its possible involvement in cerebellar ataxia. Can J Neurol Sci 1993; (Suppl 3): S578-82.
19. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-5.
20. Svetel M, Vojvodi N, Filipovi SR, Draga N, Stemi N, Kosti VS. Buspirone in the treatment of cerebellar ataxia. Srp Arh Celok Lek 1999; 127: 312-5.
21. 1A agonist, is active in cerebellar ataxia. Arch Neurol 1997; 54: 749-52.